-
Sponsored by Satyapon & PartnersSatyapon & Partners法律事務所のクリツァナ・ミントンクウム氏とシャンタヌ・アジット・タンベ氏は、タイにおける商標侵害の損害賠償請求についてのガイドを提供し、より迅速な解決と高額な賠償を実現するアプローチを提案しています。 -
Sponsored by MaiwaldChristian Meyer and Gisela Grabow of Maiwald discuss potential changes to the EU pharmaceutical regulation and their potential impact on data and market protection timelines for medicinal products
-
Sponsored by CASPatent landscape analysis helps R&D teams identify trends, optimise resources, and seize innovation opportunities. This article, originally published by CAS, explains how to leverage the right tools to stay ahead of the competition
-
Sponsored by InspicosJakob Pade Frederiksen of Inspicos says a Unified Patent Court decision not to stay a revocation action while a parallel EPO opposition proceeding takes place provides another indication of the court’s fast pace
-
Sponsored by Tilleke & GibbinsSon Thai Hoang and Linh Thi Mai Nguyen of Tilleke & Gibbins highlight the strict stance taken by the Intellectual Property Office of Vietnam on assignments conflicting with trade names and join the calls for clearer guidance
-
Sponsored by Tilleke & GibbinsThe Central Intellectual Property and International Trade Court has confirmed that a design’s overall appearance should be considered when determining its eligibility for patent protection, report Nuttaphol Arammuang and Tanapong Pongburanakit of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law reports on a decision that should provide improved guidance in determining whether patents or approved drugs are eligible for a patent term extension in South Korea
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Shipra Alisha Philip of RNA, Technology and IP Attorneys analyse how a US ruling could affect digital libraries, e-book licensing, and public access to knowledge in India
-
Sponsored by Bird & BirdEmilia Zalewska and Andrzej Stelmachowski of Bird & Bird provide insights into two matters considered by the Unified Patent Court and a Polish court concerning the imminent infringement of patent rights in the pharmaceutical industry
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
-
Sponsored by Patrinos & KilimirisManolis Metaxakis of Patrinos & Kilimiris reports on a notable judgment in the Zara trademark dispute, highlighting a radical provision in the relevant Greek legislation and the ruling’s alignment with EU case law
-
Sponsored by Adams & AdamsJames Davies and Vishen Pillay at Adams & Adams discuss IP protection strategies and ownership considerations for AI
